Clinical application of companion diagnostics

Trends in Molecular Medicine

Volumn 21, Issue 7, 2015, Pages 405-407

  Jørgensen, Jan Trøst ^a  

^a Dx Rx Institute   (Denmark)

Author keywords

Companion diagnostics; Drug efficacy; Oncology; Pharmacogenetics; Pharmacotherapy; Precision medicine

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE DRUG REACTION; ASSAY; ASTHMA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COMPANION DIAGNOSTICS ASSAY; DEPRESSION; DRUG EFFICACY; HUMAN; IMMUNOHISTOCHEMISTRY; INCONTINENCE; MOLECULAR DIAGNOSTICS; NOTE; OSTEOPOROSIS; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTIVE VALUE; PRESCRIPTION; RHEUMATOID ARTHRITIS; PERSONALIZED MEDICINE; PROCEDURES;

ANTINEOPLASTIC AGENTS; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 84933521154     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.05.003     Document Type: Note

References (6)

1. Spear B.B., et al. Clinical application of pharmacogenetics. Trends Mol. Med. 2001, 7:201-204.
2. Guidance for Industry and Food and Drug Administration Staff. In Vitro Companion Diagnostic Devices 2014, US FDA, US Department of Health and Human Services.
3. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
4. Olsen D., Jørgensen J.T. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front. Oncol. 2014, 4:105.
5. Gibson D.S., et al. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Rev. Mol. Diagn. 2015, 15:219-234.
6. Carr D.F., et al. Pharmacogenomics: current state-of-the-art. Genes 2014, 5:430-443.